Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 31.9%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 2,990,326 shares, an increase of 31.9% from the January 15th total of 2,266,456 shares. Approximately 12.7% of the shares of the company are short sold. Based on an average daily trading volume, of 961,464 shares, the short-interest ratio is currently 3.1 days. Based on an average daily trading volume, of 961,464 shares, the short-interest ratio is currently 3.1 days. Approximately 12.7% of the shares of the company are short sold.

Immix Biopharma Price Performance

Shares of Immix Biopharma stock opened at $7.33 on Monday. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $7.73. The company has a 50 day simple moving average of $5.74 and a two-hundred day simple moving average of $3.88. The firm has a market cap of $388.20 million, a PE ratio of -9.52 and a beta of 0.31.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Mizuho started coverage on Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $11.00.

Institutional Trading of Immix Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP grew its stake in shares of Immix Biopharma by 3,495.4% during the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after buying an additional 1,923,708 shares during the last quarter. Bleichroeder LP increased its stake in Immix Biopharma by 17.6% in the 4th quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock worth $5,230,000 after purchasing an additional 150,000 shares during the period. Hudson Bay Capital Management LP bought a new stake in Immix Biopharma in the fourth quarter valued at approximately $176,000. Jane Street Group LLC boosted its stake in shares of Immix Biopharma by 1,016.4% during the fourth quarter. Jane Street Group LLC now owns 167,132 shares of the company’s stock valued at $874,000 after purchasing an additional 152,162 shares during the period. Finally, Tocqueville Asset Management L.P. grew its holdings in shares of Immix Biopharma by 70.3% in the fourth quarter. Tocqueville Asset Management L.P. now owns 68,550 shares of the company’s stock worth $359,000 after purchasing an additional 28,300 shares during the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.